Up until recently, the stock has been a chronic underperformer.

Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer mentioned the stock during the episode and said: In a ...

Quick Read Pfizer (PFE) paid $9.771B in dividends against free cash flow of $9.076B in FY2025, exceeding cash generation by ...

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot because of a lack of ...

Doctors break down what you need to know about the four-dose vaccine.

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...